重组人促卵泡激素治疗对多囊卵巢综合征患者血清激素水平、排卵及妊娠的影响

Effect of recombinant human follicle-stimulating hormone on serum hormones,ovulation and pregnancy for patients with polycystic ovary syndrome

目的探讨重组人促卵泡激素(rhFSH)治疗对多囊卵巢综合征(PCOS)患者血清激素水平、排卵及妊娠率的影响。方法选择2017年6月至2018年5月在我院治疗的PCOS患者104例为研究对象,采用随机数字法分为两组,每组52例。对照组患者给予氯米芬治疗,观察组患者在对照组患者治疗的基础上加用rhFSH治疗,疗程10 d。比较两组患者的临床疗效、血清激素水平、宫颈黏液评分、子宫内膜厚度、排卵率、妊娠率及不良反应发生情况。结果治疗结束后随访12个月,观察组患者的治疗总有效率(90.38%)明显高于对照组(73.08%),差异有统计学意义(P<0.05)。治疗月经周期第21天时,两组患者的卵泡刺激素(FSH)、孕酮(P)、雌二醇(E2)水平均明显升高,观察组患者的水平显著高于对照组,差异有统计学意义(P<0.05)。治疗10 d后,两组患者的宫颈黏液评分明显增高、子宫内膜明显增厚,观察组患者的评分显著高于对照组,子宫内膜厚度显著大于对照组,差异有统计学意义(P<0.05)。观察组患者治疗月经周期的排卵率(65.38%)明显高于对照组(36.54%);随访12个月,观察组患者的妊娠率(30.77%)明显高于对照组(13.46%),差异有统计学意义(P<0.05)。治疗期间,两组患者的不良反应发生率比较差异无统计学意义(P>0.05)。结论重组人促卵泡激素治疗有利于改善多囊卵巢综合征患者的血清激素水平,促进患者排卵,提高患者的妊娠率,治疗安全性高。

Objective To explore the effect of recombinant human follicle-stimulating hormone(rhFSH) on serum hormone level, ovulation, and pregnancy rate in patients with polycystic ovary syndrome(PCOS). Method A total of 104 patients with PCOS who were treated in our hospital from June 2017 to May 2018 were selected as the research objects. The patients were divided into two groups using the random number method, with 52 cases in each group. The control group was given clomiphene for treatment, whereas the observation group was additionally administered rhFSH based on the treatment in the control group, for a ten-day treatment course. The clinical efficacy, serum hormone level, cervical mucus scores, endometrial thickness, ovulation rate, pregnancy rate, and occurrence of adverse reactions were compared between the two groups. Results Twelve-month follow-up after the end of treatment, the total effective rate of treatment in the observation group(90.38%) was significantly higher than that in the control group(73.08%), with a statistically significant difference(P<0.05). At the 21st day of the menstrual cycle, the levels of follicle-stimulating hormone(FSH), progesterone(P), and estradiol(E2) significantly increased in the two groups, and the levels of the observation group were significantly higher than those of the control group, with statistically significant differences(P<0.05). After 10 days of treatment, the cervical mucus scores and the endometrial thickness of the two groups significantly increased, and patients in the observation obtained higher cervical mucus scores, as well as a larger endometrial thickness as compared with the control group, with statistically significant differences(P<0.05). The ovulation rate(65.38%) of the menstrual cycle in the observation group was significantly higher than that in the control group(36.54%). After 12 months of follow-up, the pregnancy rate of the observation group(30.77%) was significantly higher than that of the control group(13.46%), with a statistically significant difference(P<0.05). During treatment, there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusion Recombinant human follicle-stimulating hormone therapy for patients with PCOS is beneficial to improve the serum hormone level, promote ovulation, increase the pregnancy rate of patients, and thus it is highly safe for treatment.